Cargando…

Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines

The bone-seeking radiopharmaceutical Xofigo (Radium-223 dichloride) has demonstrated both extended survival and palliative effects in treatment of bone metastases in prostate cancer. The alpha-particle emitter Ra-223, targets regions undergoing active bone remodeling and strongly binds to bone hydro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abramenkovs, Andris, Hariri, Mehran, Spiegelberg, Diana, Nilsson, Sten, Stenerlöw, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489499/ https://www.ncbi.nlm.nih.gov/pubmed/36126563 http://dx.doi.org/10.1016/j.tranon.2022.101543

Ejemplares similares

Removal of heat-sensitive clustered damaged DNA sites is independent of double-strand break repair
por: Abramenkovs, Andris, et al.
Publicado: (2018)

The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells
por: Spiegelberg, Diana, et al.
Publicado: (2015)

The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach
por: Spiegelberg, Diana, et al.
Publicado: (2020)

Nanostructure of Clustered DNA Damage in Leukocytes after In-Solution Irradiation with the Alpha Emitter Ra-223
por: Scherthan, Harry, et al.
Publicado: (2019)

$^{223}$Ra nuclear spectroscopy in $^{14}$C cluster radioactivity
por: Hourany, E, et al.
Publicado: (1995)

α-Particle-induced DNA damage tracks in peripheral blood mononuclear cells of [(223)Ra]RaCl(2)-treated prostate cancer patients
por: Schumann, S., et al.
Publicado: (2021)

The HSP90 inhibitor onalespib potentiates (177)Lu-DOTATATE therapy in neuroendocrine tumor cells
por: Lundsten, Sara, et al.
Publicado: (2019)

Laser isotope separation of (223)Ra
por: Suryanarayana, M. V.
Publicado: (2023)

Radiobiological effects of the alpha emitter Ra-223 on tumor cells
por: Bannik, Kristina, et al.
Publicado: (2019)

Fine Structures in $^{14}C$ Emission of $^{223}Ra$ and $^{224}Ra$
por: Hourani, E, et al.
Publicado: (1991)

Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells
por: Sahlberg, Sara Häggblad, et al.
Publicado: (2014)

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
por: Nilsson, Sten
Publicado: (2016)

Temperature effects on alpha radioactivity of $^{223}$Ra
por: Huber, Gerhard, et al.
Publicado: (2006)

Ra223 in Bone Metastases with Osteolytic Activity
por: Costa, Renato Patrizio, et al.
Publicado: (2018)

(223)Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice
por: Dizdarevic, Sabina, et al.
Publicado: (2018)

Fine structure in 14C emission from 223Ra and 224Ra
por: Hourani, E, et al.
Publicado: (1991)

Differential responses to (223)Ra and Alpha-particles exposure in prostate cancer driven by mitotic catastrophe
por: Guerra Liberal, Francisco D. C., et al.
Publicado: (2022)

DNA damage in leukocytes after internal ex-vivo irradiation of blood with the α-emitter Ra-223
por: Schumann, Sarah, et al.
Publicado: (2018)

Ultrastructural Analysis of Cancer Cells Treated with the Radiopharmaceutical Radium Dichloride ([(223)Ra]RaCl(2)): Understanding the Effect on Cell Structure
por: Diniz Filho, Joel Félix Silva, et al.
Publicado: (2023)

Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [(223)Ra]RaCl(2) therapy
por: Sraieb, Miriam, et al.
Publicado: (2020)

Response to (223)Ra-dichloride in castration-resistant prostate cancer with bone metastasis: A case report
por: Cabrera, Montserrat Estorch, et al.
Publicado: (2016)

Comparing absorbed doses and radiation risk of the α-emitting bone-seekers [(223)Ra]RaCl(2) and [(224)Ra]RaCl(2)
por: Lassmann, Michael, et al.
Publicado: (2023)

Repair of α-particle-induced DNA damage in peripheral blood mononuclear cells after internal ex vivo irradiation with (223)Ra
por: Göring, Lukas, et al.
Publicado: (2022)

Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model
por: Spiegelberg, Diana, et al.
Publicado: (2015)

Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection
por: Den, Robert B., et al.
Publicado: (2019)

Radiopharmacokinetic modelling and radiation dose assessment of (223)Ra used for treatment of metastatic castration-resistant prostate cancer
por: Höllriegl, Vera, et al.
Publicado: (2021)

Pretreatment PSA levels affects the completion rate of Ra-223 treatment
por: Utsumi, Nobuko, et al.
Publicado: (2021)

Improved (223)Ra Therapy with Combination Epithelial Sodium Channel Blockade
por: Abou, Diane S., et al.
Publicado: (2021)

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
por: van der Doelen, Maarten J., et al.
Publicado: (2021)

Safety and Survival Outcomes of (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior (223)Ra treatment: The RALU Study
por: Rahbar, Kambiz, et al.
Publicado: (2023)

Submarine groundwater discharge data at meter scale ((223)Ra, (224)Ra, (226)Ra, (228)Ra and (222)Rn) in Indian River Bay (Delaware, US)
por: Duque, Carlos, et al.
Publicado: (2019)

Precise study of fine structure in $^{14}$C emission from $^{223}$Ra
por: Hourani, E, et al.
Publicado: (1992)

Revision of the NIST Standard for (223)Ra: New Measurements and Review of 2008 Data
por: Zimmerman, B. E., et al.
Publicado: (2015)

(223)Ra-dichloride therapy of bone metastasis: optimization of SPECT images for quantification
por: Benabdallah, Nadia, et al.
Publicado: (2019)

(177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study)
por: Rahbar, Kambiz, et al.
Publicado: (2023)

Current approaches to incorporation of radium-223 in clinical practice
por: Parker, Chris, et al.
Publicado: (2018)

Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Design and Evaluation of (223)Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy–Part I
por: Czerwińska, Malwina, et al.
Publicado: (2020)

Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with (223)Ra: PARABO, a Prospective, Noninterventional Study
por: Palmedo, Holger, et al.
Publicado: (2023)

Scintigraphic Load of Bone Disease Evaluated by DASciS Software as a Survival Predictor in Metastatic Castration-resistant Prostate Cancer Patients Candidates to 223RaCl Treatment
por: Frantellizzi, Viviana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_05n0flvjjcuthbo71h3svep3f0